PPT-Modelling the economic impact of precision medicine on childhood cancer management a

Owen Tan 1 Deborah Schofield 1 Rupendra Shrestha 1 1 GenIMPACT Centre for Economic Impacts of Genomic Medicine Macquarie Business School Macquarie University Australia Presenting at . Ben Phillips: Principal Research Fellow, NATSEM, 21 Feb 2015. 2. What are microsimulation models?. Tools to simulate government programs, demographic and economic change, current or alternative situation. USING CGE MODELS FOR POVERTY AND INEQUALITY ANALYSIS. Jeff Round. February 2012. Poverty impact analysis. Impact of economic shocks on poverty. Various manifestations of poverty. money-metric (income, expenditure, assets), health, . From Promise to Practice. PRECISION ONCOLOGY IS THE FUTURE OF CANCER CARE.. Tumor genome data informs cancer treatment and clinical pathways, resulting in better health outcomes.. New cancer therapies target the molecular pathways that lead to tumor genesis and progression.. Using 5-2-1-0 Messages at Well-Child Visits. Jerica Berge, PhD, MPH, Associate Professor. Lisa Trump, MS, LAMFT, Intern. Renee . Crichlow. , MD, . Assistant Professor. University of Minnesota North Memorial Family Medicine Residency Program. 1. 2015 Precision Medicine Initiative: . Two Components: Cancer & National Cohort. “. An emerging approach for disease prevention and treatment that takes into account people’s individual variations in genes, environment, and lifestyle”. Jeremy Warner . MD, MS. Assistant Professor of Medicine and Biomedical . Informatics. Vanderbilt University. June 26, 2017. Three questions every cancer patient asks. Who’s like me?. How long have I got?. Robert A. Somer, MD. Head, Medical Oncology and Hematology. Director, Office of Clinical Research. MD Anderson Cancer Center- Cooper. What is Cancer?. Official Definition: A malignant proliferation of cells that is a result of a . are Failing Most Persons with Cancer by Blocking. Access. . To Precision Diagnostics and Drugs. Workshop: Pharmaceutical Pricing and Marketing: Markets Versus Regulation. ASU University. Tempe, Arizona. Introduction. How Has Precision Medicine Changed the Treatment Landscape in Oncology?. Selection of Biomarkers in Drug Development. Methods to Identify Driver Mutations. Which Method Should Be Used?. Impactful Data from a Highly Burdened Population. Principal Investigator. B Mark Evers, MD. Key Personnel. Eric B. Durbin, DrPH, MS, Project Lead. Jay Christian, PhD. Erin Haynes, PhD. John L. . Villano. ValueAwareness,Testing & Educate stakeholders on the value including physicians, pathologists, payers, patient Develop EU and UK-wide guidelines to promote the use of comprehensive testing at various Karen L. Edwards, . PhD. Professor, Dept. of Epidemiology. School of Medicine. University of . California, Irvine. Irvine, CA. Outline. Two National Initiatives . Precision Medicine Initiative . Cancer . the case of SWITCH. Tim Callan. Economic and Social Research Institute. Overview. Context: the role of SWITCH. S. imulating . W. elfare and . I. ncome . T. ax . CH. anges. A tour of the SWITCH model. Biochemistry. qxsang@chem.fsu.edu. Biochemical, Molecular, and Pathological Mechanisms of Cancer, Stroke, Obesity, and Stem Cell Differentiation, and Cancer Biomarker and Drug Discovery for Precision .